What is Relmada Therapeutics Inc (RLMD) stock price today?

Relmada Therapeutics Inc (RLMD) currently trades at $7.52 per share. The stock has a market capitalization of $759.40M and a P/E ratio of —x.

Is RLMD stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Relmada Therapeutics Inc has a Smart Value Score of 22/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 1/9 and Altman Z-Score is —.

Is Relmada Therapeutics Inc financially healthy?

Relmada Therapeutics Inc's Piotroski F-Score is 1/9 (weak financial health). The Altman Z-Score of — places it in the —.

RLMD

Relmada Therapeutics Inc

NASDAQ: RLMD · HEALTHCARE · BIOTECHNOLOGY

$7.52

+2.04% today

Updated 2026-04-30

Market cap

$759.40M

P/E ratio

—

P/S ratio

9,001.90x

EPS (TTM)

$-1.45

Dividend yield

—

52W range

$0 – $8

Volume

2.1M

Market cap

$759.40M

P/E ratio

—

P/S ratio

9,001.90x

EPS (TTM)

$-1.45

Dividend yield

—

52W range

$0 – $8

Volume

2.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

5.0

Quality

C+

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$12.80

+70.21%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Piotroski 1/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-14.60M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-157.04M	$-98.79M	$-79.98M	$-57.39M	$-19.87M
EPS	—	—	—	—	$-1.45
Free cash flow	$-103.80M	$-51.66M	$-51.76M	$-45.79M	$-14.60M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
RLMD	$759.40M	22	4.3	3.0	5.0	5.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Relmada Therapeutics Inc trades at $7.52. Our Smart Value Score of 22/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score.

Frequently asked questions

What is Relmada Therapeutics Inc's stock price?

Relmada Therapeutics Inc (RLMD) trades at $7.52.

Is Relmada Therapeutics Inc overvalued?

Smart Value Score 22/100 (Grade F, Strong Sell).

What is the price target of Relmada Therapeutics Inc (RLMD)?

The analyst target price is $12.80, representing +70.2% upside from the current price of $7.52.

Piotroski F-Score?

1/9 — weak financial health.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.relmada.com

Quick metrics

P/S ratio9,001.90x

ROE-25.60%

Beta0.83

50D MA$6.12

200D MA$3.48

Shares out0.10B

Float0.01B

Short ratio—

Avg volume2.1M

Performance

1 week+1.66%

1 month+5.89%

3 months+88.49%

YTD+52.59%

1 year—

3 years—

5 years—

Compare

RLMD vs LLY →RLMD vs JNJ →RLMD vs ABBV →Stock screener →